Searched for
ONCOLOGY INJECTABLE MANUFACTURING
For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- Government may lift price cap on cancer drugs making them costlier by up to 50%India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy age...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
- Cenexi recovery, new product launches and capacity additions power Gland Pharma outlookGland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 croreQuadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...
- Zydus Lifesciences gets USFDA nod for Leuprolide Acetate injectionZydus Lifesciences has secured final approval from the US health regulator for its generic Leuprolide Acetate injection. This medication is...
- BDR Pharmaceuticals plans $100 mn expansion in the US with manufacturing buyoutsBDR Pharmaceuticals is set to broaden its presence in the US through acquisitions of manufacturing facilities, backed by a $100 million inv...
- Aurobindo Pharma to hive off injectables businessIndian drugmaker Aurobindo Pharma has decided to hive off its injectables business into a wholly owned subsidiary.
- Strides Arcolab gets approval for facility, anti-bacterial injectionDrug firm Strides Arcolab today said it has received approval from the European authorities for its Bangalore-based oncology facility.
- Venus: Phase IV of Baddi projectVenus Remedies has completed Phase IV of the Baddi project comprising two dedicated plants for specialty formulations.
- Zenotech to market Ranbaxy’s oncology products in N AmericaRanbaxy on Wednesday announced a strategic tie-up with Hyderabad-based Zenotech Laboratories for marketing the latter’s oncology products i...
Load More
